Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

Galan
 
RBR-8h7q82
RCTivermectinchloroquine and derivativesCOVID-19 severe or criticallysome concern
53/115 suggested
  • inconclusive 6 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 86 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
Galan
 
RBR-8h7q82
RCTivermectinhydroxychloroquineCOVID-19 severe or criticallysome concern
53/115 suggested
  • inconclusive 6 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 86 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
Okumuş
 
NCT04646109
RCTivermectincontrolCOVID-19 severe or criticallyhigh
30/30 inconclusive
    1 study excluded by filtering options (0 RCT / 1 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).